ArticleJournal of microbiology (Seoul, Korea)2018
Comparative analysis of the gut microbiota in distinct statin response patients in East China.
Article in Journal of microbiology (Seoul, Korea), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action.Molecules (Basel, Switzerland) · 2024Pooled it
- Gut bacterial microbiome composition and statin intake-A systematic review.Pharmacology research & perspectives · 2020Pooled it
- Microbes and medicines: interrelationships between pharmaceuticals and the gut microbiome.Gut microbes · 2026Review
- Gut microbiome-blood cholesterol crosstalk: towards personalized strategies for dyslipidemia.Folia microbiologica · 2026Review
- Pharmacomicrobiomics of Non-Antibiotic Drugs: Mechanisms and Clinical Consequences of Gut Microbiota Alterations.Pharmaceutics · 2026Review
- Microbiome-Associated Drug Response Variability in Heart Failure Treatment.Life (Basel, Switzerland) · 2026Review
- Therapeutic potential of atorvastatin in ischemic stroke: an investigation into its anti-inflammatory effect by targeting the gut-brain axis.Journal of translational medicine · 2025Article
- Statin therapy associated Lactobacillus intestinalis attenuates pancreatic fibrosis through remodeling intestinal homeostasis.NPJ biofilms and microbiomes · 2025Article
- The Bidirectional Relationship Between Cardiovascular Medications and Oral and Gut Microbiome Health: A Comprehensive Review.Microorganisms · 2024Review
- The Role of Gut Microbiota in the Etiopathogenesis of Multiple Chronic Diseases.Antibiotics (Basel, Switzerland) · 2024Review
- Review
- Role of Gut Microbiome in Atherosclerosis: Molecular and Therapeutic Aspects.Current cardiology reviews · 2023Review
- Human Gut Microbiota in Coronary Artery Disease: A Systematic Review and Meta-Analysis.Metabolites · 2022Review
- The promise of the gut microbiome as part of individualized treatment strategies.Nature reviews. Gastroenterology & hepatology · 2022Review
- Targets of statins intervention in LDL-C metabolism: Gut microbiota.Frontiers in cardiovascular medicine · 2022Review
- How Brain Infarction Links With the Microbiota-Gut-Brain Axis: Hints From Studies Focusing on the Risk Factors for Ischemic Stroke.Frontiers in neuroscience · 2022Review
- The Role of Gut Microbiota on Cholesterol Metabolism in Atherosclerosis.International journal of molecular sciences · 2021Review
- A Comprehensive Analysis of Genomics and Metagenomics in a Heterozygote Familial Hypercholesterolemia Family.Frontiers in cellular and infection microbiology · 2021Article
- Article
- Unraveling Host-Gut Microbiota Dialogue and Its Impact on Cholesterol Levels.Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Statin response shows great interindividual variations. Recently, emerging studies have shown that gut microbiota is linked to therapeutic responses to drugs, including statins. However, the association between the gut bacteria composition and statin response is still unclear. In this study, gut microbiota of 202 hyperlipidemic patients with statin sensitive (SS) response and statin resistant (SR) response in East China were investigated by high throughput sequencing to compare the gut bacteria composition and biodiversity in distinct statin response patients. Higher biodiversity was detected in Group SS than Group SR. Specifically, group SS showed significantly increased proportion of genera Lactobacillus (P = 0.001), Eubacterium (P = 0.004), Faecalibacterium (P = 0.005), and Bifidobacterium (P = 0.002) and decreased proportion of genus Clostridium (P = 0.001) compared to Group SR. The results indicated that higher gut biodiversity was associated with statin sensitive response. The increased genera Lactobacillus, Eubacterium, Faecalibacterium, Bifidobacterium, and decreased genus Clostridium in patient gut microbiota may predict patient's statin response, and hence may guide statin dosage adjustments.
Indexed as
Identifiers
30484158What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.